Leqembi’s approval for Alzheimer’s treatment marks a turning point

On April 15, the agency approved Leqembi. File photo: Eisai Co Ltd via AP
Try from €1.25 / week
SUBSCRIBEOn April 15, the agency approved Leqembi. File photo: Eisai Co Ltd via AP
THIS week marks a watershed moment as the European Commission approves Leqembi — the first drug authorised by the European Medicines Agency to slow progression of early-stage Alzheimer’s.
This landmark decision follows a protracted and controversial process, including an extraordinary escalation to an appeal committee. On April 15, the agency approved Leqembi just weeks after rejecting a similar drug, Kisunla, based on the benefit-risk profile. Both Leqembi and Kisunla are available in other regions such as Britain.
CONNECT WITH US TODAY
Be the first to know the latest news and updates
Newsletter
Sign up to the best reads of the week from irishexaminer.com selected just for you.
Newsletter
Keep up with stories of the day with our lunchtime news wrap and important breaking news alerts.
Newsletter
Sign up to the best reads of the week from irishexaminer.com selected just for you.
Thursday, October 2, 2025 - 8:00 AM
Thursday, October 2, 2025 - 8:00 AM
Wednesday, October 1, 2025 - 10:00 PM
© Examiner Echo Group Limited